177 related articles for article (PubMed ID: 19183836)
21. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
[TBL] [Abstract][Full Text] [Related]
22. Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome.
Takei T; Itabashi M; Tsukada M; Sugiura H; Moriyama T; Kojima C; Shiohira S; Shimizu A; Karasawa K; Amemiya N; Kawanishi K; Ogawa T; Uchida K; Tsuchiya K; Nitta K
Intern Med; 2010; 49(19):2065-70. PubMed ID: 20930431
[TBL] [Abstract][Full Text] [Related]
23. Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.
Pepe J; Isidori AM; Falciano M; Iaiani G; Salotti A; Diacinti D; Del Fiacco R; Sbardella E; Cipriani C; Piemonte S; Raimo O; Biondi P; Biamonte F; Lenzi A; Minisola S
Endocrine; 2014 Nov; 47(2):456-62. PubMed ID: 25104272
[TBL] [Abstract][Full Text] [Related]
24. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
25. Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.
Yamada S; Takagi H; Tsuchiya H; Nakajima T; Ochiai H; Ichimura A; Iwata H; Toriyama T
Yakugaku Zasshi; 2007 Sep; 127(9):1491-6. PubMed ID: 17827929
[TBL] [Abstract][Full Text] [Related]
26. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
27. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Dundar U; Kavuncu V; Ciftci IH; Evcik D; Solak O; Cakir T
J Bone Miner Metab; 2009; 27(4):464-70. PubMed ID: 19301089
[TBL] [Abstract][Full Text] [Related]
28. Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol.
Kanaji A; Higashi M; Namisato M; Ando K; Nakagawa M; Yato Y; Ichinose H; Sakamaki T; Yamada H
J Bone Miner Metab; 2005; 23(1):90-4. PubMed ID: 15616900
[TBL] [Abstract][Full Text] [Related]
29. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
Bobba R; Adachi JD
Clin Interv Aging; 2007; 2(3):275-82. PubMed ID: 18044178
[TBL] [Abstract][Full Text] [Related]
30. The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.
Shiraishi A; Miyabe S; Nakano T; Umakoshi Y; Ito M; Mihara M
BMC Musculoskelet Disord; 2009 Jun; 10():66. PubMed ID: 19527501
[TBL] [Abstract][Full Text] [Related]
31. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
32. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
[TBL] [Abstract][Full Text] [Related]
33. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Sebba AI; Bonnick SL; Kagan R; Thompson DE; Skalky CS; Chen E; de Papp AE;
Curr Med Res Opin; 2004 Dec; 20(12):2031-41. PubMed ID: 15706659
[TBL] [Abstract][Full Text] [Related]
34. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
Takata S; Abbaspour A; Yonezu H; Yasui N
J Med Invest; 2007 Feb; 54(1-2):35-40. PubMed ID: 17380012
[TBL] [Abstract][Full Text] [Related]
35. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
[TBL] [Abstract][Full Text] [Related]
36. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
37. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.
Ringe JD; Farahmand P; Schacht E
Rheumatol Int; 2013 Mar; 33(3):637-43. PubMed ID: 22527138
[TBL] [Abstract][Full Text] [Related]
38. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
39. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
